ArticleCancer immunology, immunotherapy : CII2023

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer.

Maud Rijnders et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.